Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
HONG KONG, July 4, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company’s progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases.These achievements not only mark the accelerated implementation of Everest Medicines’ “dual-engine” strategy, but also reflect the company’s evolution from an initial license-in model to a balanced approach that integrates in-house discovery with global partnerships and in-licensing—focusing on high-value therapeutic areas and the development of first-in-class or best-in-class assets.Everest is among a select group of biopharmaceutical companies worldwide with full in-house capabilities across the entire mRNA development chain. The company has successfully localized and …